Subscribe free

Cytoreductive Surgery & Peritoneum ·

Improved Odds of Cytoreductive Surgery with HIPEC and Survival for Colorectal Peritoneal Metastases

Findings from a nationwide population-based study revealed that patients diagnosed in hipec centers had better odds of undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) and improved survival rates before 2016. However, after national efforts to increase awareness and improve referral networks, these differences were no longer present between patients diagnosed in hipec and referring centers from 2016 to 2021, indicating equal access to care and similar chances of survival at a national level.

Journal Article by van der Ven RGFM, van den Heuvel TBM (…) de Hingh IHJT et 10 al. in Ann Surg Oncol

© 2024. The Author(s).

read the whole article in Ann Surg Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Cytoreductive Surgery & Peritoneum.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Cytoreductive Surgery & Peritoneum

The latest stitches

Ann Surg Oncol28 Aug 2026

Prophylactic HIPEC Improves Survival in Advanced Colorectal Cancer

Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) significantly enhances peritoneal metastasis-free survival and disease-free survival in patients with locally advanced colorectal cancer, though overall survival rates and complication rates remain unchanged.

All papers in Cytoreductive Surgery & Peritoneum →